Clinicians Globally Have Used Mallinckrodt's Unique and Highly Specialized Extracorporeal Photopheresis (ECP) System to Deliver More than 1 Million Patient Treatments Globally STAINES-UPON-THAMES, England, May 3, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading...
Read More
Approval granted for reimbursement of Extracorporeal Photopheresis (ECP) for Bronchiolitis Obliterans Syndrome (BOS) derived from lung transplantation. First approval of a Health Technology Appraisal for ECP in BOS by a...
Read More
Adds depth and durability to Mallinckrodt's Specialty Brands segment; further diversifies its portfolio with an innovative high-value, high-margin drug-device system used in hospitals and major medical centers in more than...
Read More
-- Enters into definitive agreement to acquire Therakos, Inc. for $1.325 billion from The Gores Group, LLC ---Transaction expected to be accretive by no less than $0.10 per share to...
Read More